Lanreotide Injection 120 mg/0.5 mL
Cipla is recalling Lanreotide Injection 120 mg/0.5 mL due to the presence of particulate matter.
Contact your healthcare provider if you have experienced any problems that may be related to using this drug product. Return the product to the place of purchase or contact the manufacturer for further instructions.
Recall at a glance
- Quantity recalled
- 15,221 syringes
Why it was recalled
Cipla is recalling Lanreotide Injection 120 mg/0.5 mL due to the presence of particulate matter. This product was distributed nationwide.
Is mine affected?
Check the NDC or UPC and strength printed on the package. Yours is affected if it matches one below.
Lanreotide Injection
- Strength
- 120 mg
- NDC / UPC
- NDC 69097-870-67
Where it was sold
Distributed nationwide.
Timeline
- Firm initiated recall
- Publicly announced
- Listed on Recall Canary
- Summary updated
Official source
Other recent recalls from Cipla USA, Inc.
Editorial summary by Recall Canary · summary updated 2026-06-11 · primary source: U.S. Food and Drug Administration · severity reflects the agency's published classification